AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody, and is also developing an expanded Phase 2 program. COM902, Compugen’s high-affinity anti-TIGIT antibody was licensed in 2018 to AstraZeneca for exclusive use in bi-specific and multi-specific antibody products, excluding PVRIG- and/or PVRL2- TIGIT-bispecific products
PreMarket Prep Stock Of The Day: Nailing The Palantir Price Action
Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.
